Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × OTHER × lutetium Lu 177 dotatate × Clear all

Phase

Phase 2 25 Phase 1 6 Phase 1/2 4 Phase 3 3 Phase NA 2 Phase EARLY_PHASE1 1 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Cisplatin 48 Fluorouracil 41 Cyclophosphamide 40 Oxaliplatin 36 Capecitabine 33 Docetaxel 32 Drug Therapy 29 Gemcitabine 28 Radiotherapy 26 Paclitaxel 24 Leucovorin 21 Carboplatin 21 Dexamethasone 19 Doxorubicin 17 apatinib 15 Etoposide 15 Cytarabine 15 Methotrexate 14 Magnetic Resonance Spectroscopy 13 Epirubicin 13 Radiation 12 Busulfan 12 Letrozole 11 Decitabine 11 Bevacizumab 11 camrelizumab 10 Surgical Procedures, Operative 10 Neoadjuvant Therapy 10 Irinotecan 10 Folfox protocol 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03590119 2022-11-08

LUTIA

UMC Utrecht

Phase 2/3 Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡